Shares of Genedrive PLC (LON: GDR) today fell 9.56% despite the company reporting a significant milestone for its coronavirus testing kit.
The company reported that ist 96 SARS-CoV-2 testing equipment had been verified to work with its collaboration partner Beckman Coulter Life Sciences’ RNA extraction equipment, which can now be used in Genedrive’s workflow.
The next stage for the two companies is to release the solution in stages starting with swab-based tests followed by saliva tests.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
However, the stock’s selloff could have been triggered by David Budd’s comments that it will take some time before the saliva tests can get approval from the US Food & Drug Administration given the strict guidelines imposed by the regulator.
Gendedrive’s CEO, David Budd explained that: “Our initial US evaluation site is currently being installed following the completion of our internal validation studies, after which they will validate the end-to-end solution as required. We will obtain regulatory approvals prior to a final solution release.”
Genedrive share price
Genedrive shares today fell 9.56% to trade at 123p having dropped from yesterday’s closing price of 136p.
People who read this also read:
